CAS 211096-49-0

N-(2-Bromophenyl)-N'-(4-cyano-1H-1,2,3-benzotriazol-7-yl)urea

Description:

N-(2-Bromophenyl)-N'-(4-cyano-1H-1,2,3-benzotriazol-7-yl)urea is a chemical compound characterized by its unique structure, which includes a urea moiety linked to a 2-bromophenyl group and a 4-cyano-1H-benzotriazole. This compound typically exhibits properties such as moderate solubility in organic solvents and potential biological activity, making it of interest in pharmaceutical and agrochemical research. The presence of the bromine atom and the cyano group can influence its reactivity and interaction with biological targets. Additionally, the benzotriazole ring is known for its stability and ability to form hydrogen bonds, which may enhance the compound's efficacy in various applications. Its molecular structure suggests potential uses in areas such as drug development, where the unique combination of functional groups can lead to novel therapeutic agents. As with many synthetic compounds, safety and handling precautions should be observed due to potential toxicity or reactivity.

Formula: C₁₄H₉BrN₆O

Synonyms:

• Sb-265610

Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-

CAS: 211096-49-0

Formula: C₁₄H₉BrN₆O

Purity: 98%

Color and Shape: Solid

Molecular weight: 357.1649

Ref: IN-DA002L5G

SB-265610

CAS: 211096-49-0

SB-265610

Purity: ≥95%

Molecular weight: 357.16g/mol

Ref: 54-BUP09200

SB-265610

CAS: 211096-49-0

SB-265610 (GSK-CXCR2) is a nonpeptide and allosteric CXCR2 antagonist.

Formula: C₁₄H₉BrN₆O

Purity: 99.5%

Color and Shape: Solid

Molecular weight: 357.16

Ref: TM-T16850

SB-265610

CAS: 211096-49-0

SB-265610 is a selective inhibitor of the EGF receptor, which binds to the epidermal growth factor (EGF) receptor. SB-265610 prevents the binding of EGF to its receptor, thereby inhibiting tumor cell proliferation and inducing apoptosis. SB-265610 has been shown to inhibit angiogenic factors and cause an antimicrobial effect in breast cancer cells by blocking the CXCR2 chemokine receptors. It also increases the amount of time before atherosclerotic lesions progress to heart disease or cardiac death.

Formula: C₁₄H₉BrN₆O

Purity: Min. 95%

Molecular weight: 357.16 g/mol

Ref: 3D-LIA09649